

The logo for the Association for Accessible Medicines (AAM) features the lowercase letters 'aam' in a bold, white, sans-serif font. Below the letters, the full name 'Association for Accessible Medicines' is written in a smaller, white, sans-serif font. The logo is set against a solid blue rectangular background.

**aam**  
Association for Accessible Medicines

The logo for The Biosimilars Council consists of a circular icon on the left containing three stylized human figures in white, holding hands. To the right of the icon, the words 'The Biosimilars Council' are stacked vertically in a white, sans-serif font. Below this, the text 'A Division of the Association for Accessible Medicines' is written in a smaller, white, sans-serif font.

The  
**Biosimilars  
Council**  
A Division of the Association for Accessible Medicines

# Leading on Biosimilars

---

**2017 AAM Biosimilars Council Conference**

# **AAM Welcome and Introduction**

**Christine Simmon**

Senior Vice President, Policy & Strategic Alliances, AAM  
Executive Director, Biosimilars Council

# Our Sponsors:

## Host Sponsors:

---



---

### Amenity Sponsor:

### Mobile App Sponsor:

### Lanyard Sponsor:

### Room Key Sponsor:



Breakfast Sponsor:

Gift Sponsor:

Wifi Sponsor:



**Lachman**  
CONSULTANTS

**SANDOZ** A Novartis  
Division

Publication Partners:



# Significant Growth at The Biosimilars Council and AAM

- Strong AAM Support
- New Dedicated Staff
- AAM Rebranding Explicitly Supports Biosimilars



Chester "Chip" Davis, Jr.  
President & Chief Executive Officer



Chris Bowlin  
Senior Vice President, Government Affairs



Jeffrey K. Francer  
Senior Vice President, General Counsel



David Gaugh, R.Ph.  
Senior Vice President, Sciences & Regulatory Affairs



Christine Simmon  
Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council



Michael Brzica  
Vice President, Federal Government Affairs



Craig Burton  
Vice President, Policy



Allen Goldberg  
Vice President, Communications



Carrie Hartgen  
Vice President, State Government Affairs



Erik Komendant  
Vice President, Federal Government Affairs



Anna McDermott-Vitak  
Vice President, Corporate Development & Administration



Lisa Parks, R.Ph.  
Vice President, Sciences & Regulatory Affairs

## Government Affairs

Brynna Clark  
Senior Director, State Affairs

John Billings  
Senior Director, Federal Government Affairs

Kristin Murphy  
Director, Federal Government Affairs

Erin Archer  
Senior Manager, State Government Affairs

Christian Cruz  
Senior Manager, Federal Government Affairs

## Sciences and Regulatory Affairs

Mark Hendrickson  
Senior Director, Sciences & Regulatory Affairs

Ashlee Koonce  
Associate Manager, Sciences & Regulatory Affairs

## Policy and Strategic Alliances

TJ Garrigan  
Senior Director, Policy

Sara Skubikowski  
Director, Strategic Alliances

## Joseph Stewart

Senior Manager, [The Biosimilars Council](#)

## Communications

Erica Klinger  
Director, Marketing

Meetings and Marketing

Jennifer Soup  
Director, Meetings & Marketing

Aquera Agee  
Associate Manager, Meetings

## Operations

Kathy Altman  
Executive Assistant to the President

Rachelle Kosky  
Senior Director, Finance & Operations

Jewel Smith  
Director, Operations

Culley Stine  
Senior Manager, Administration & Operations

## Legal

Rachel Sher  
Deputy General Counsel

**“AAM works to ensure more generic and biosimilar medicines are more accessible to more people who need them.”**

# The Biosimilars Council Member Companies



# Patient Access Study Release

## **“Biosimilars in the United States: Providing More Patients Greater Access to Lifesaving Medicines”**

- Patient Access Study done on behalf of the Biosimilars Council by Avalere Health
- Report indicates that 1.2 million U.S. patients could gain access to biologics by 2025 as the result of biosimilar availability.
- The report also suggests that women, lower income, and elderly individuals would particularly benefit from access to biosimilar medicines.

# Updated Handbook



An educational resource for patients, policymakers and health professionals.



# Conference Day 1 Agenda

## TUESDAY, SEPTEMBER 12, 2017 – CONFERENCE DAY 1

- 7:30 a.m.                      **Registration** – Thurgood Marshall Foyer
- 7:30 a.m. – 8:30 a.m.        **Networking Breakfast** – Marriott Foyer
- 8:30 a.m. – 8:45 a.m.        **AAM Welcome and Introduction** – Thurgood Marshall Ballroom  
**Christine Simmon**  
Senior Vice President, Policy & Strategic Alliances, AAM  
Executive Director, Biosimilars Council
- 8:45 a.m. – 9:15 a.m.        **Biosimilars Council Chair Welcome**  
**Bruce Leicher**  
General Counsel, Senior Vice President and Secretary  
Momenta Pharmaceuticals, Inc.
- 9:15 a.m. – 10:00 a.m.      **Regulatory Expectations: Biosimilars and Biologics**  
**Maria-Teresa Gutierrez-Lugo, Ph.D.**  
Acting Review Chief, OPQ, OBP, DBRRIII, CDER  
Food and Drug Administration
- 10:00 a.m. – 10:30 a.m.    **Networking Refreshment Break** – Thurgood Marshall Foyer

10:30 a.m. – 12:00 p.m.

**Market Access, Market Success**

Moderator: **Elizabeth Jex**

Attorney Advisor, Office of Policy Planning  
Federal Trade Commission

**Rachel Sher**

Deputy General Counsel  
AAM

**Crystal Kuntz**

Vice President Policy and Regulatory Affairs  
America's Health Insurance Plans

**Andrew Mulcahy**

Policy Researcher; Associate Research Department Director  
RAND Corporation

12:00 p.m. – 1:15 p.m.

**Luncheon** – Marriott Foyer

1:15 p.m. – 2:15 p.m.

**Delivering Biosimilars Access in Europe**

**Adrian van den Hoven**

Director General, Medicines for Europe

2:15 p.m. – 3:15 p.m.

**The Promise of Biosimilars: Patient Advocates Educating Around Patient Care**

**Moderator: *Edward Li, Pharm.D., MPH, BCOP***

Professor, Department of Pharmacy Practice  
University of New England College of Pharmacy

***Michele McCourt***

Senior Director, CancerCare Co-Payment Assistance Foundation  
CancerCare

***Claire Saxton***

Senior Director, Education  
Cancer Support Community

***Laura Wingate***

Senior Vice President, Education, Support & Advocacy  
Crohn's & Colitis Foundation

***Christy Gamble, J.D., DrPH, MPH***

Director, Health Policy and Legislative Affairs  
Black Women's Health Imperative

3:15 p.m. – 3:30 p.m.

***Networking Refreshment Break***

- 3:30 p.m. – 4:15 p.m. **The View from Wall Street**  
*Douglas Tsao, MPH*  
Director, Senior Research Analyst, U.S. Specialty Pharmaceuticals  
Barclays Capital, Inc.
- 4:15 p.m. – 4:45 p.m. **USP Biologics Program Overview**  
*Fouad Atouf, Ph.D.*  
Vice President, Science - Global Biologics  
U.S. Pharmacopeial Convention
- 4:45 p.m. – 6:45 p.m. **Networking Reception** – Wardman East Lawn